FDA approves DUPIXENT for COPD, offering a new treatment targeting inflammatory pathways.
Regeneron and Sanofi's drug DUPIXENT has been approved by the FDA for treating Chronic Obstructive Pulmonary Disease (COPD), marking its sixth approved use. Unlike traditional treatments, DUPIXENT targets specific inflammatory pathways, showing a 30% reduction in severe exacerbations and improved lung function. This breakthrough addresses a subset of COPD patients, offering a more targeted treatment option.
November 12, 2024
5 Articles